WEKO3
アイテム
Carbon-ion re-irradiation for recurrences after initial treatment of stage I non-small cell lung cancer with carbon-ion radiotherapy.
https://repo.qst.go.jp/records/48373
https://repo.qst.go.jp/records/48373f29b52f8-e749-4403-b9ad-03552fd02aee
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-11-16 | |||||
| タイトル | ||||||
| タイトル | Carbon-ion re-irradiation for recurrences after initial treatment of stage I non-small cell lung cancer with carbon-ion radiotherapy. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Karube, Masataka
× Karube, Masataka× Yamamoto, Naoyoshi× Tsuji, Hiroshi× Kanematsu, Nobuyuki× Nakajima, Mio× H, Yamashita× Nakagawa, K× Kamada, Tadashi× 軽部 雅崇× 山本 直敬× 辻 比呂志× 兼松 伸幸× 中嶋 美緒× 鎌田 正 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | PURPOSE: \nTo investigate carbon-ion radiotherapy (CIRT) for in-field recurrence of stage I non-small cell lung cancer (NSCLC) initially treated with CIRT. \nMATERIALS AND METHODS: \nFrom January 2007 to March 2014, patients initially treated for stage I NSCLC with CIRT and relapsed in-field were candidates. Overall survival (OS) rate, local control (LC) rate, progressive free survival (PFS) rate, dose to the lungs and skin, and adverse effects were analyzed. \nRESULTS: \nTwenty-nine patients were eligible. Median age at re-irradiation was 74years (range 53-90). Median observation period from the first day of re-irradiation was 29months (4-88months). Median prescribed dose was 46.0Gy (RBE) as initial treatment and 66.0Gy (RBE) in 12 fractions as re-irradiation. Two-year OS, LC, and PFS rates after re-irradiation were 69.0% (95% CI: 50.3-83.0), 66.9% (95% CI: 47.5-81.9), and 51.7% (95% CI: 34.1-68.9). Median skin maximum dose was 53.8Gy (RBE) (range 4.4-103.1) and median of mean lung dose was 7.3Gy (RBE) (range 2.6-14.0). There were no severer than grade 2 adverse effects except one (3.4%) grade 3 bacterial pneumonia, which was not considered radiation-induced. \nCONCLUSION: \nCIRT for stage I NSCLC local recurrence is an acceptable definitive re-treatment. |
|||||
| 書誌情報 |
Radiotherapy and Oncology 巻 125, 号 1, p. 31-35, 発行日 2017-08 |
|||||
| 出版者 | ||||||
| 出版者 | Elsevier B.V. | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0167-8140 | |||||
| PubMed番号 | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 28784437 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1016/j.radonc.2017.07.022 | |||||
| 関連サイト | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | http://dx.doi.org/10.1016/j.radonc.2017.07.022 | |||||
| 関連名称 | http://dx.doi.org/10.1016/j.radonc.2017.07.022 | |||||
